NEW YORK (GenomeWeb) – Quanterix announced it has licensed two assays from Banyan Biomarkers to bolster its research-use test menu for traumatic brain injury (TBI).
Under the terms of the agreement, Lexington, Massachusetts-based Quanterix will develop the Banyan UCH-L1 and GFAP assays for its Simoa single-molecule array technology. It will also incorporate the biomarkers into multiplex assays for research use in neurology.
Financial and other terms of the agreement were not disclosed.
"Simoa technology can detect biomarkers associated with brain injury and disease at much earlier stages to understand the long-term effects and disease pathology," the firm said in a statement. CEO Kevin Hrusovsky added that the firm will be "best positioned to develop the most accurate and predictive tests for concussions, [chronic traumatic encephalitis], TBI, and other neurological disorders."
Both Quanterix and Banyan received money from the GE and National Football League Head Health Challenge Grant program.
The deal helps Quanterix with its goal to double its test menu to 80 assays by the end of the year.